Abstract
1. Centers for Disease Control. Food and Drug Administration approval of use of a Haernophilus b conjugate vaccine for infants. MMWR 1990;39:925-6. 2. Centers for Disease Control, Food and Drug Administration approval of use of Haemophilus b conjugate vaccine in infants. MMWR 1990;39:698-9. 3. Boase J, Alexander R. Decline in Haemophilus influenzae type b meningitis--Seattle-King County, Washington, 1984-1989. MMWR 1990;39:924-5. 4. Madore DV, Johnson CL, Phipps DC, et al. Safety and immunologic response to Haemophilus influenzae type b oligosaccharide-CRM197 conjugate vaccine in 1to 6-month old infants, Pediatrics 1990;85:331-7, 5. Madore DV, Johnson CL, Phipps DC, et al. Safety and immunogenicity of Haemophilus influenzae type b oligosaccharideCRM197 conjugate vaccine in infants aged 15 to 23 months. Pediatrics 1990;86:527-34. 6. Anderson P. Intrinsic tritium labeling of the capsular polysaccharide antigen of Haemophilus influenzae type b. J Immunol 1978;120:866-70. 7. K~iyhty H, Peltola H, Karenko V, Miikel/i PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983;147:1100. 8. Kgyhty H. Reimmunization with H. influenzae type b conjugate vaccine or capsular polysaccharide vaccine after primary immunization with conjugate vaccine; Presented at Third International Symposium on Epidemiology, Pathogenesis, and Prevention of Haemophilus influenzae Disease. Veldhoven, The Netherlands, Sept 1990.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call